Skip to main content

WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
221 (255 working days)
Active ingredients
Registration type

WEGOVY is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of:

  • &ge30 kg/m2 (obesity), or
  • &ge27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties – Clinical trials).

Help us improve the Therapeutic Goods Administration site